Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA Oncology

• Publication date

  2017-10-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaoncol.2017.2899PMID 28983557PMCID PMC5784452
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

  2016cited by this paper
• Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

  2016cited by this paper
• Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

  2015cited by this paper
• Implications of mismatch repair-deficient status on management of early stage colorectal cancer.

  2015cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

  2014cited by this paper
• Prognostic Impact of Deficient DNA Mismatch Repair and KRAS and BRAFV600E Mutations in Patients with Lymph-Node-Positive Colon Cancer

  2014cited by this paper
• Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer.

  2014cited by this paper
• Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

  2013cited by this paper
• Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.

  2012cited by this paper
• Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

  2012cited by this paper
• Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

  2010cited by this paper
• Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

  2010cited by this paper
• Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.

  2010cited by this paper
• Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

  2009cited by this paper
• Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.

  2007cited by this paper
• A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model

  2007cited by this paper

• Molecular Targets in Metastatic Colorectal Cancer: A Review

  2025cites this paper
• ST6GAL1‐Mediated Sialylation Stabilizes PD‐L1 and Drives Immunosuppressive Tumor Microenvironment in Colorectal Cancer

  2025cites this paper
• Targeting gut microbiota and arginase boosts MEK inhibitors’ enhancement of antitumour immunity via MHC-I upregulation in colorectal cancer

  2025cites this paper
• pMMR-MSS/MSI-L Colorectal Cancer: Latest Advances and Future Directions in Immunotherapy —A Review

  2025cites this paper
• Current Status of Precision Medicine in Colorectal Cancer in Japan

  2025cites this paper
• Complete blood counts as potential risk factors of early dissemination to liver and lungs in resected colorectal cancer: a retrospective cohort study

  2025cites this paper
• Phenotypic plasticity and increased infiltration of peripheral blood-derived TREM1+ mono-macrophages following radiotherapy in rectal cancer

  2025cites this paper
• Mucinous Ovarian Cancer: A Review of Diagnosis and Treatment

  2025cites this paper
• Organotropic metastasis in colorectal cancer: integrating molecular pathways with therapeutic opportunities

  2025cites this paper
• The co-location of MARCO + macrophages and SPOCK1 + fibroblasts contributes to the poor prognosis and undesirable immunotherapy response in colorectal cancer

  2025cites this paper
• Nationwide Real-World Data of Microsatellite Instability and/or Mismatch Repair Deficiency in Cancer: Prevalence and Testing Patterns

  2024cites this paper
• Advancements in Lynch Syndrome Management: Applying Immunotherapy for Therapeutic Success

  2024cites this paper
• Clinical, pathological, and adjuvant chemotherapy use differences among microsatellite unstable and microsatellite stable colon cancers

  2024cites this paper
• The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study

  2024cites this paper
• Role of Microsatellite Instability as Pan-Cancer Agnostic Marker of Solid Tumours in Personalized Medicine

  2024cites this paper
• Narrative review of neoadjuvant therapy in patients with locally advanced colon cancer

  2024cites this paper
• Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review

  2024cites this paper
• ctDNA-guided adjuvant immunotherapy in colorectal cancer.

  2024cites this paper
• The assessment of adjuvant chemotherapy benefits after D3 lymphadenectomy in patients with colon cancer: a propensity score matching study

  2024cites this paper
• Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer

  2024cites this paper
• Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.

  2024cites this paper
• Endothelial cell heterogeneity in colorectal cancer: tip cells drive angiogenesis

  2024cites this paper
• Mitochondrial DNA Copy Number as a Biomarker for Guiding Adjuvant Chemotherapy in Stages II and III Colorectal Cancer Patients with Mismatch Repair Deficiency: Seeking Benefits and Avoiding Harms

  2024cites this paper
• SPP1+ macrophages in colorectal cancer: Markers of malignancy and promising therapeutic targets

  2024cites this paper
• Field synopsis of environmental and genetic risk factors of sporadic early-onset colorectal cancer and advanced adenoma.

  2023cites this paper
• Single cell AI-based detection of DNA mismatch repair deficiency in 1,988 colorectal cancers reveals prognostic and predictive value in the SCOT trial

  2023cites this paper
• A liquid biopsy signature of circulating extracellular vesicles-derived RNAs predicts response to first line chemotherapy in patients with metastatic colorectal cancer

  2023cites this paper
• Chemokine- and chemokine receptor-based signature predicts immunotherapy response in female colorectal adenocarcinoma patients

  2023cites this paper
• Single-cell analysis unveils activation of mast cells in colorectal cancer microenvironment

  2023cites this paper
• DNA damage repair molecular subtype derived immune signature applicable for the prognosis and immunotherapy response prediction in colon cancer

  2023cites this paper
• Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.

  2023cites this paper
• Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer

  2023cites this paper
• A narrative review of prognostic indices in the evaluation of gastrointestinal cancers

  2023cites this paper
• Neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer: Current status and future prospects

  2023cites this paper
• Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice

  2023cites this paper
• Case Report: Chemoimmunotherapy in microsatellite-instability-high advanced goblet cell carcinoma of the colon

  2023cites this paper
• CAF-derived exosomal lncRNA FAL1 promotes chemoresistance to oxaliplatin by regulating autophagy in colorectal cancer.

  2023cites this paper
• MCM5 is an oncogene of colon adenocarcinoma and promotes progression through cell cycle control.

  2023cites this paper
• Radiologic T staging of colon cancer: renewed interest for clinical practice

  2023cites this paper
• Therapeutic landscape and future direction of metastatic colorectal cancer

  2023cites this paper
• Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods

  2022cites this paper
• Colorectal carcinoma: From molecular pathology to clinical practice

  2022cites this paper
• Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy

  2022cites this paper
• Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.

  2022cites this paper
• Sistema de reparación de errores de emparejamiento en carcinoma colorrectal. Frecuencia, fenotipo y seguimiento

  2022cites this paper
• Clinicopathologic significance of DNA mismatch repair protein status in endometrial cancer.

  2022cites this paper
• Microsatellite instability and chemosensitivity in solid tumours

  2022cites this paper
• Mismatch repair system in colorectal cancer. Frequency, cancer phenotype, and follow-up.

  2022cites this paper
• Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer

  2022cites this paper
• Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer

  2022cites this paper
• Molecular Pathology of Gastric Cancer

  2022cites this paper
• Comprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer

  2022cites this paper
• Tissue microarrey: a potential cost-effective approach for mismatch repair testing in colorectal cancer

  2022cites this paper
• Development and validation of a new stage-specific nomogram model for predicting cancer-specific survival in patients in different stages of colon cancer: A SEER population-based study and external validation

  2022cites this paper
• Neue medikamentöse Konzepte bei Patienten mit kolorektalen Karzinomen und Mikrosatelliteninstabilität

  2022cites this paper
• Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection

  2021cites this paper
• The impact of Molecular profile on the LYMPHATIC SPREAD pattern in STAGE III COLON CANCER.

  2021cites this paper
• Using immunotherapy in prostate cancer patients – more than sipuleucel-T 2 3

  2021cites this paper
• Serum Tumor Markers Combined With Clinicopathological Characteristics for Predicting MMR and KRAS Status in 2279 Chinese Colorectal Cancer Patients: A Retrospective Analysis

  2021cites this paper
• Interaction between Microsatellite Instability (MSI) and Tumor DNA Methylation in the Pathogenesis of Colorectal Carcinoma

  2021cites this paper
• Immunotherapy in colorectal cancer: current achievements and future perspective

  2021cites this paper
• SLF1 polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer.

  2021cites this paper
• The tumor microenvironment and immune responses in prostate cancer patients

  2021cites this paper
• Integrated Analysis of Expression and Prognostic Values of Acyl-CoA Dehydrogenase short-chain in Colorectal Cancer

  2021cites this paper
• Sporadic and Inherited Colorectal Cancer: How Epidemiology and Molecular Biology Guide Screening and Treatment

  2021cites this paper
• Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy

  2021cites this paper
• Controlling for cellular heterogeneity using single-cell deconvolution of gene expression reveals novel markers of colorectal tumors exhibiting microsatellite instability

  2021cites this paper
• The impact of molecular profile on the lymphatic spread pattern in stage III colon cancer

  2021cites this paper
• Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair

  2020cites this paper
• CMAR_A_248069 2863..2873

  2020cites this paper
• Microsatellite instability as a unique characteristic of tumors and a predictor of response to immune therapy

  2020cites this paper
• Molecular Targets for the Treatment of Metastatic Colorectal Cancer

  2020cites this paper
• Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future

  2020cites this paper
• Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer.

  2020cites this paper
• A case of Turcot’s syndrome type 1 with loss of immunoexpression of MSH6 in colon cancer and liver metastasis due to secondary somatic mutation in coding mononucleotide (C)8 tract: a case report

  2020cites this paper
• Evaluation of Concordance Between Deficient Mismatch Repair and Microsatellite Instability Testing and Their Association with Clinicopathological Features in Colorectal Cancer

  2020cites this paper
• Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

  2020cites this paper
• Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).

  2020cites this paper
• A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level

  2020cites this paper
• SEOM clinical guideline on hereditary colorectal cancer (2019)

  2020cites this paper
• Prognostic and predictive role of DNA mismatch repair status in stage II‐III colorectal cancer: A systematic review and meta‐analysis

  2020cites this paper
• Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: a retrospective clinical study

  2020cites this paper
• Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions

  2020cites this paper
• Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review

  2020cites this paper
• Immune scores in colorectal cancer: Where are we?

  2020cites this paper
• PNN and KCNQ1OT1 Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients

  2020cites this paper
• Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer.

  2020cites this paper
• Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.

  2020cites this paper
• Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.

  2020cites this paper
• [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]

  2019cites this paper
• SSBP1 Upregulation In Colorectal Cancer Regulates Mitochondrial Mass

  2019cites this paper
• SSBP1 Upregulation In Colorectal Cancer Regulates Mitochondrial Mass

  2019cites this paper
• Standardized Pathology Report for Colorectal Cancer, 2nd Edition

  2019cites this paper
• Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma.

  2019cites this paper
• Association of KRAS mutation with tumor deposit status and overall survival of colorectal cancer

  2019cites this paper
• Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?

  2019cites this paper
• The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer

  2019cites this paper
• Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies

  2019cites this paper
• Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial

  2019cites this paper
• Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single‐center retrospective study of 1,834 Chinese patients with Stage I–IV colorectal cancer

  2019cites this paper